Skip to main content
Journal cover image

The clinical presentation and treatment of MOG antibody disease at a single academic center: A case series.

Publication ,  Journal Article
Brayo, P; Hartsell, FL; Skeen, M; Morgenlander, J; Eckstein, C; Shah, S
Published in: J Neuroimmunol
December 15, 2019

OBJECTIVES: To describe the clinical presentation of MOG antibody disease (MOG-AD) in a series of patients at a single academic center. METHODS: We performed a retrospective review of patients with MOG antibodies. RESULTS: We review the clinical presentation of 11 patients with MOG antibodies. In patients seen at Duke University Health System with MOG antibodies, the most common presentation was optic neuritis. Rituximab was the most used treatment for long-term management. CONCLUSIONS: Our case series highlights the common presentation of MOG antibody disease (MOG-AD) at a single academic medical center.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Neuroimmunol

DOI

EISSN

1872-8421

Publication Date

December 15, 2019

Volume

337

Start / End Page

577078

Location

Netherlands

Related Subject Headings

  • Treatment Outcome
  • Rituximab
  • Retrospective Studies
  • Optic Neuritis
  • Neurology & Neurosurgery
  • Myelin-Oligodendrocyte Glycoprotein
  • Middle Aged
  • Male
  • Immunologic Factors
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Brayo, P., Hartsell, F. L., Skeen, M., Morgenlander, J., Eckstein, C., & Shah, S. (2019). The clinical presentation and treatment of MOG antibody disease at a single academic center: A case series. J Neuroimmunol, 337, 577078. https://doi.org/10.1016/j.jneuroim.2019.577078
Brayo, Petra, F Lee Hartsell, Mark Skeen, Joel Morgenlander, Christopher Eckstein, and Suma Shah. “The clinical presentation and treatment of MOG antibody disease at a single academic center: A case series.J Neuroimmunol 337 (December 15, 2019): 577078. https://doi.org/10.1016/j.jneuroim.2019.577078.
Brayo P, Hartsell FL, Skeen M, Morgenlander J, Eckstein C, Shah S. The clinical presentation and treatment of MOG antibody disease at a single academic center: A case series. J Neuroimmunol. 2019 Dec 15;337:577078.
Brayo, Petra, et al. “The clinical presentation and treatment of MOG antibody disease at a single academic center: A case series.J Neuroimmunol, vol. 337, Dec. 2019, p. 577078. Pubmed, doi:10.1016/j.jneuroim.2019.577078.
Brayo P, Hartsell FL, Skeen M, Morgenlander J, Eckstein C, Shah S. The clinical presentation and treatment of MOG antibody disease at a single academic center: A case series. J Neuroimmunol. 2019 Dec 15;337:577078.
Journal cover image

Published In

J Neuroimmunol

DOI

EISSN

1872-8421

Publication Date

December 15, 2019

Volume

337

Start / End Page

577078

Location

Netherlands

Related Subject Headings

  • Treatment Outcome
  • Rituximab
  • Retrospective Studies
  • Optic Neuritis
  • Neurology & Neurosurgery
  • Myelin-Oligodendrocyte Glycoprotein
  • Middle Aged
  • Male
  • Immunologic Factors
  • Humans